IN2014DN08215A - - Google Patents

Download PDF

Info

Publication number
IN2014DN08215A
IN2014DN08215A IN8215DEN2014A IN2014DN08215A IN 2014DN08215 A IN2014DN08215 A IN 2014DN08215A IN 8215DEN2014 A IN8215DEN2014 A IN 8215DEN2014A IN 2014DN08215 A IN2014DN08215 A IN 2014DN08215A
Authority
IN
India
Prior art keywords
osteoclasts
pharmaceutical composition
antibody
inhibiting
gene
Prior art date
Application number
Other languages
English (en)
Inventor
Yoshiharu Hiruma
Takako Kimura
Hironari Shimizu
Original Assignee
Daiichi Sankyo Companyltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Companyltd filed Critical Daiichi Sankyo Companyltd
Publication of IN2014DN08215A publication Critical patent/IN2014DN08215A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN8215DEN2014 2012-03-30 2013-03-29 IN2014DN08215A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012078842 2012-03-30
PCT/JP2013/059654 WO2013147213A1 (fr) 2012-03-30 2013-03-29 Anticorps anti-siglec15 ayant une cdr modifiée

Publications (1)

Publication Number Publication Date
IN2014DN08215A true IN2014DN08215A (fr) 2015-05-15

Family

ID=49260454

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8215DEN2014 IN2014DN08215A (fr) 2012-03-30 2013-03-29

Country Status (20)

Country Link
US (1) US9464133B2 (fr)
EP (1) EP2832857B1 (fr)
JP (1) JP6059205B2 (fr)
KR (1) KR20150003170A (fr)
CN (1) CN104334722A (fr)
AU (1) AU2013241003A1 (fr)
BR (1) BR112014024269A8 (fr)
CA (1) CA2868959A1 (fr)
ES (1) ES2660472T3 (fr)
HK (1) HK1204657A1 (fr)
IL (1) IL234883A0 (fr)
IN (1) IN2014DN08215A (fr)
MX (1) MX2014011828A (fr)
NZ (1) NZ631509A (fr)
PH (1) PH12014502187A1 (fr)
RU (1) RU2014143798A (fr)
SG (1) SG11201405966PA (fr)
TW (1) TW201343672A (fr)
WO (1) WO2013147213A1 (fr)
ZA (1) ZA201407079B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
SG10201605897RA (en) 2007-10-11 2016-09-29 Daiichi Sankyo Co Ltd ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
AU2013293062A1 (en) 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
WO2015192214A1 (fr) * 2014-06-18 2015-12-23 Alethia Biotherapeutics Inc. Anticorps anti-siglec-15 destinés à être utilisés dans le traitement de l'ostéogénèse imparfaite
WO2018143336A1 (fr) * 2017-02-03 2018-08-09 住友化学株式会社 Procédé de détection du cancer du pancréas
JP7181535B2 (ja) * 2017-06-30 2022-12-01 国立大学法人北海道大学 成長障害を生じない小児骨粗鬆症治療薬
CN113817057B (zh) * 2020-06-19 2024-02-20 盛禾(中国)生物制药有限公司 一种抗siglec15抗体及其应用
CA3209169A1 (fr) * 2021-02-23 2022-09-01 Shanghai Jemincare Pharmaceutical Co., Ltd. Preparation de proteine de liaison de siglec-15 et son utilisation
CN113577283A (zh) * 2021-07-19 2021-11-02 河北医科大学第三医院 Siglec-15抑制剂在制备防治骨巨细胞瘤药物中的应用
CN118043351A (zh) * 2021-08-31 2024-05-14 上海医药集团股份有限公司 靶向Siglec15的抗原结合蛋白及其用途
WO2023241538A1 (fr) * 2022-06-13 2023-12-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anticorps anti-siglec15 et leurs utilisations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
EP2336168A1 (fr) 1997-04-15 2011-06-22 Sankyo Company Limited Nouvelle protéine et et procédé pour le produire
WO1999054342A1 (fr) 1998-04-20 1999-10-28 Pablo Umana Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
ES2651952T3 (es) 2000-10-06 2018-01-30 Kyowa Hakko Kirin Co., Ltd. Células que producen unas composiciones de anticuerpo
AU2002233994A1 (en) 2000-11-08 2002-05-21 Incyte Genomics, Inc. Secreted proteins
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
EP1369479A4 (fr) 2001-02-15 2004-12-08 Mochida Pharm Co Ltd Nouvelle molecule d'adhesion cellulaire specifique de leucocyte active
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
WO2003048305A2 (fr) 2001-11-13 2003-06-12 Incyte Genomics, Inc. Recepteurs et proteines associees aux membranes
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
SI1583830T1 (sl) 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
US7405037B2 (en) 2004-05-07 2008-07-29 Lonza Walkersville, Inc. Methods and tools for detecting collagen degradation
JP4604184B2 (ja) 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
SG10201605897RA (en) 2007-10-11 2016-09-29 Daiichi Sankyo Co Ltd ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
CN102272306B (zh) * 2009-04-09 2017-12-26 第一三共株式会社 抗‑Siglec‑15抗体
MX2013003828A (es) 2010-10-05 2013-06-28 Daiichi Sankyo Co Ltd Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.

Also Published As

Publication number Publication date
EP2832857A1 (fr) 2015-02-04
KR20150003170A (ko) 2015-01-08
CN104334722A (zh) 2015-02-04
BR112014024269A8 (pt) 2017-07-25
JPWO2013147213A1 (ja) 2015-12-14
WO2013147213A1 (fr) 2013-10-03
JP6059205B2 (ja) 2017-01-11
IL234883A0 (en) 2014-12-31
RU2014143798A (ru) 2016-05-27
BR112014024269A2 (fr) 2017-06-20
PH12014502187A1 (en) 2014-12-10
EP2832857B1 (fr) 2018-01-03
ZA201407079B (en) 2016-02-24
ES2660472T3 (es) 2018-03-22
US9464133B2 (en) 2016-10-11
TW201343672A (zh) 2013-11-01
MX2014011828A (es) 2014-12-10
EP2832857A4 (fr) 2016-02-17
NZ631509A (en) 2016-09-30
US20150056189A1 (en) 2015-02-26
SG11201405966PA (en) 2014-11-27
AU2013241003A1 (en) 2014-10-16
HK1204657A1 (en) 2015-11-27
CA2868959A1 (fr) 2013-10-03

Similar Documents

Publication Publication Date Title
IN2014DN08215A (fr)
MY152033A (en) Anti-siglec-15 antibody
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
HK1200449A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases bub1
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
MX2015007921A (es) Compuestos heterociclicos novedosos como inhibidores de bromodominio.
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
MY181828A (en) Bicyclically substituted uracils and the use therapy
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
MX337549B (es) Derivados de insulina que contienen enlaces disulfuro adicionales.
MY163257A (en) Humanised anti-cd52 antibodies
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
MX2015008877A (es) Conjugados de disulfuro mixto de compuestos de tienopiridina y sus usos.
IN2014DN08385A (fr)
IN2014DN00123A (fr)
IN2014DN03010A (fr)
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
TR201200212A2 (tr) Risedronat içeren geliştirilmiş formülasyonlar.
UA66925U (en) orthopedic spinal support
LV14461A (lv) Līdzeklis efektīvai augsta glutamāta līmeņa pazemināšanai asinīs
UA97054C2 (ru) Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ
TN2014000085A1 (en) Substituted annellated pyrimidine and the use thereof
MX2015008454A (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.